SUMMARY SUSPENSION/NOTICE OF OPPORTUNITY FOR HEARING
TERMINAL DISTRIBUTOR OF DANGEROUS DRUGS LICENSE

IN THE MATTER OF: **CASE NO. A-2025-0299**

Ree's Bar of Beauty LLC **License No. 02-60003000**
c/o Sherrie Rey, RN
2339 Broadview Road
Cleveland, OH 44109

-THIS IS A RED INK STAMP-
I certify this to be a true and exact copy of the original document on file with the Ohio State Board of Pharmacy.
Steven W. Schierholt, Esq., Executive Dir.
Date: 9/30/2025
-MUST HAVE BOARD SEAL TO BE OFFICIAL-

September 30, 2025

Dear Ree's Bar of Beauty and Sherrie Rey, RN:

You are hereby notified, in accordance with Section 119.07 of the Ohio Revised Code (ORC), the Ohio Board of Pharmacy (Board) hereby SUMMARILY SUSPENDS Ree's Bar of Beauty's license as a Terminal Distributor of Dangerous Drugs (TDDD) under authority of Sections 4729.57 and 4729.571 of the Ohio Revised Code.

Furthermore, the Board finds that based upon the facts set forth in the Allegations Section, there is clear and convincing evidence of a danger of immediate and serious harm to others due to Ree's Bar of Beauty's method used to possess or distribute dangerous drugs. As such, the Board summarily suspends Ree's Bar of Beauty's license as a Terminal Distributor of Dangerous Drugs.

JURISDICTION

1. Pursuant to section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the Board has the authority to suspend, revoke, restrict, limit, or refuse to grant or renew any license issued pursuant to Sections 4729.54 and 4729.55 of the ORC to practice as a TDDD in the state of Ohio. Further, pursuant to Section 4729.55(E), the Board shall refuse to issue a future license to an applicant for a TDDD if the applicant, or any agent (including any owner or responsible person) or employee of the applicant, has been found to have violated any of the specified laws identified therein or any rule of the board, absent proof of adequate safeguards assuring prevention of a recurrence of the violation. Additionally, Section 4729.57 of the Ohio Revised Code grants the Board the authority to impose a monetary penalty or forfeiture not to exceed in severity any fine designated under the Revised Code for a similar offense or $1,000 if the acts committed have not been classified as an offense by the ORC.

2. Pursuant to Section 4729.571(A)(1) of the ORC and the rules adopted thereunder, the Board has the authority to suspend a terminal distributor's license without a hearing if it determines that there is clear and convincing evidence of a danger of immediate and serious harm to others due to the method used by the terminal distributor to possess or distribute dangerous drugs.

3. Ree's Bar of Beauty LLC, located at 2339 Broadview Rd., Cleveland, Ohio 44109, is a licensed TDDD under license number 02-60003000 and lists Travis McDonald, MD [Ohio Medical Board license number 35C.001603] as the Responsible Person. Sherrie Rey, RN [Ohio Nursing Board number RN.420850; Cosmetology and Barber Board number EST.984846] is the CEO/owner.

ALLEGATIONS

1. On or about September 8, 2025, the Board conducted an inspection at Ree's Bar of Beauty (Ree's), located at 2339 Broadview Rd., Cleveland, Ohio (TDDD 02-60003000). CEO/Owner Sherrie Ray, RN, was present.

2. During the inspection, it was identified that Ree's had purchased two (2) compounded vials of semaglutide/glycerine/B12 5/5/.5mg (3ml) and one (1) compounded vial of tirzepatide 30 mg/ml+B12+Glycine .5mg/ml (2ml) from an unlicensed source.

    a. The dangerous drugs were ordered on or about July 30, 2025, and delivered on or about August 1, 2025, from Go My Docs, which is an entity that is not a licensed wholesale drug distributor, outsourcing facility, compounding pharmacy, or drug manufacturer in the United States and does not have Food and Drug Administration (FDA) manufacturer registration.

    b. The vials are labeled with a lot and expiration date, list of ingredients, and "RX Only Compounded Medication," and "Manufactured by: Go My Docs National Medical Compounding Association."

    c. RN Rey admitted to, and provided an administration record for, a self-injection of a dose of the compounded tirzepatide on September 1, 2025.

3. The inspection conducted on September 8, 2025, resulted in seven warnings requiring written responses for violations including the following:

    a. Purchased dangerous drugs from unlicensed source:

        i. Illegal purchases of compounded semaglutide and compounded tirzepatide were made from Go My Docs, an unlicensed distributor (see Allegation #2).

        ii. A documented query of the eLicense database was not completed.

    b. Multiple punctured multi-dose vials in the active drug stock were not properly labeled with date opened or beyond use date (BUD).

c. The clinic lacked documented orders for the administration of dangerous drugs.

i. RN Rey stated during the inspection that she had “good faith exams” completed for patients but did not document the verbal orders from her available prescribers.

ii. According to information obtained from APRN Davetta Todd following the 9/8/25 inspection, APRN Todd signed paperwork to be available to see Ree’s patients but never evaluated any clinic patients or issued any orders.

d. Compounding violations.

i. Immediate use compounds for IV hydration sometimes include more than 3 drugs.

ii. A prescriber was not on site for the compounding, final check, or administration of the compounded dangerous drugs.

iii. The clinic’s compounding records were incomplete. Paper records of administration of IV hydration did not contain all required information, including but not limited to, the date/time of preparation, assigned BUD, or the positive identification of the compounder.

b. Responsible Person.

i. The listed Responsible Person (RP), Dr. Travis McDonald, was hired through GuardianMD, a company that contracts medical directors with clinics. From on or about August 28, 2024, through on or about May 30, 2025, Dr. McDonald served as the clinic’s medical director/RP.

ii. During the 9/8/25 inspection, RN Rey reported reporting to Board staff that Dr. McDonald was at the clinic three to four times a quarter.

iii. On 9/9/25 and 9/10/25, Board staff spoke with Dr. McDonald and GuardianMD Chief Compliance Officer Mary Bolden, who confirmed the following:

1. Dr. McDonald had never been to the clinic.

2. Dr. McDonald was in place to sign protocols, but he never met with, issued orders, or engaged in any prescribing for the clinic’s patients.

3. Dr. McDonald’s collaborative practice agreement with APRN Todd ended on or about November 18, 2024.

4. RN Rey ended her contract with GuardianMD, effective May 30, 2025, which terminated Dr. McDonald’s association with the clinic; however, Dr. McDonald remains listed as the RP as of the date of the issuance of this Notice.

iv. The clinic failed to notify the Board of the change of RP, failed to obtain a new RP, and has been operating without an RP since May 31, 2025.

POTENTIAL VIOLATIONS OF LAW

1. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of section 3715.52(A) of the ORC, Prohibited acts, each, a misdemeanor of the fourth degree, each punishable by a maximum penalty of $2,000 if committed by an organization: The following acts and causing them are prohibited:

   a. The manufacture, sale, or delivery, holding or offering for sale of any food, drug, device, or cosmetic that is adulterated[1] or misbranded,[2] ORC Section 3715.52(A)(1); and/or

   b. The adulteration or misbranding of any food, drug, device, or cosmetic, ORC Section 3715.52(A)(2); and/or

   c. The receipt in commerce of any food, drug, device, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise, ORC Section 3715.52(A)(3).

2. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of Section 4729.51(F) of the ORC, effective April 9, 2025, Selling, purchasing, distributing, or delivering dangerous or investigational drugs – No licensed terminal distributor of dangerous drugs or person that is exempt from licensure under section 4729.541 of the Revised Code shall purchase dangerous drugs or investigational drugs or products from any person other than a licensed manufacturer, outsourcing facility, third-party logistics provider, repackager, or wholesale distributor, punishable by a maximum penalty of $5,000 if committed by an organization.

3. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of Section 4729.60(B) of the ORC, effective October 3, 2023, Verification of license prior to transactions – Before a licensed terminal distributor of dangerous drugs may purchase dangerous drugs at wholesale, the terminal distributor shall query the roster established pursuant to section 4729.59 of the Revised Code to confirm the seller is licensed to engage in the sale or distribution of dangerous drugs at wholesale, each violation punishable by a maximum penalty of $1,000 if committed by an organization.

4. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-3-04 of the OAC, as effective March 1, 2019, Verification of licensure prior to sale or purchase, each violation punishable by a maximum penalty of $1,000:

   a. Before a terminal distributor of dangerous drugs may purchase dangerous drugs at wholesale, the terminal distributor shall query the board's online roster (available on the

[1] ORC Section 3715.63 – When drug or device is adulterated.
[2] ORC Section 3715.64 – Misbranded drug or device.

board's website: www.pharmacy.ohio.gov) to confirm any of the following:

i. The seller is licensed to engage in the sale of dangerous drugs in accordance with section 4729.52 of the Revised Code, OAC Rule 4729:5-3-04(A)(1); and/or

ii. The seller is licensed to engage in the occasional sale or distribution of dangerous drugs at wholesale in accordance with rule 4729:5-3-09 of the Administrative Code, OAC Rule 4729:5-3-04(A)(2); and/or

b. If no documented query is conducted before a purchase is made, it shall be presumed that the purchase of dangerous drugs by the terminal distributor is in violation of section 4729.51 of the Revised Code, OAC Rule 4729:5-3-04(B).

5. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following divisions of Rule 4729:5-3-06 of the OAC, as effective March 1, 2019, Storage of adulterated drugs, each violation punishable by a maximum penalty of $1,000:

a. To prevent their use, adulterated drugs, as defined in agency 4729 of the Administrative Code, shall be stored in a separate and secure area apart from the storage of drugs used for dispensing, personally furnishing, compounding and administration, OAC Rule 4729:5-3-06.

6. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-19-03 of the OAC, as effective February 4, 2021, Security, control and storage of dangerous drugs, each violation punishable by a maximum penalty of $1,000:

a. The security and control of dangerous drugs is the responsibility of the responsible person on the terminal distributor of dangerous drugs license and the terminal distributor of dangerous drugs, OAC Rule 4729:5-19-03(A); and/or

b. Upon the initial puncture of a multiple-dose vial containing a drug, the vial shall be labeled with a beyond-use date or date opened. The beyond-use date for an opened or entered (e.g., needle punctured) multiple-dose container with antimicrobial preservatives is twenty-eight days, unless otherwise specified by the manufacturer. A multiple-dose vial that exceeds its beyond-use date shall be deemed adulterated, OAC Rule 4729:5-19-03(L); and/or

c. Adulterated drugs, including expired drugs, shall be stored in accordance with rule 4729:5-3-06 of the Administrative Code, OAC Rule 4729:5-19-03(M).

7. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-3-14(A) of the OAC, as effective March 1, 2020, General security requirements, each violation punishable by a maximum penalty of $1,000:

a. All terminal distributors of dangerous drugs shall provide effective controls and procedures to ensure supervision and control of dangerous drugs, as required in division (B) of section 4729.55 of the Revised Code, and adequate safeguards to ensure that dangerous drugs are

being distributed in accordance with all state and federal laws, as required in section 4729.55 of the Revised Code, OAC Rule 4729:5-3-14(A)(2).

8. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-19-04 of the OAC, Record Keeping, as effective March 1, 2020, each violation punishable by a maximum penalty of $1,000:

    a. A clinic or prescriber office shall keep a record of all dangerous drugs received, administered, personally furnished, disposed, sold or transferred, OAC Rule 4729:5-19-04(A); and/or

    b. Records of administration shall contain the name, strength, dosage form, and quantity of the dangerous drugs administered, the name and date of birth of the person to whom or for whose use the dangerous drugs were administered, the date of administration, and either:

        i. For non-controlled substance dangerous drugs: the identification of the health care professional administering the drug, OAC Rule 4729:5-19-04(E)(1)(a); and/or

        ii. Records of dangerous drugs administered which become a permanent part of the patient's medical record shall be deemed to meet the requirements of this paragraph, OAC Rule 4729:5-19-04(E)(2); and/or

        iii. Records of dangerous drugs administered by a health care professional, acting within the professional's scope of practice, who is not a prescriber shall include documentation of an order issued by a prescriber or protocol authorizing the administration of the drug. An order that is a permanent part of the patient's medical record shall be deemed to meet the requirements of this paragraph. Orders for the administration of controlled substances shall be documented using positive identification, OAC Rule 4729:5-19-04(E)(3); and/or

    c. All records maintained in accordance with this rule and rule 4729:5-19-03 of the Administrative Code shall be readily retrievable and shall be kept on-site for a period of three years, OAC Rule 4729:5-19-04(J).

9. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following sections of Rule 4729:7-3-04 of the OAC, as effective April 2, 2021, Immediate-use, sterile non-hazardous drugs compounded by a prescriber, each violation punishable by a maximum penalty of $1,000:

    a. The responsible person of a facility where a prescriber is engaged in the compounding of immediate-use, sterile non-hazardous dangerous drug preparations in accordance with paragraph (B) of this rule shall be responsible for all the following:

        i. Developing and implementing appropriate compounding procedures, OAC Rule 4729:7-3-04(A)(1); and/or

ii. Overseeing facility compliance with this rule, OAC Rule 4729:7-3-04(A)(2); and/or

iii. Compliance with Title 21 U.S.C. section 353a (11/27/2013) and all other applicable federal and state laws, regulations and rules, OAC Rule 4729:7-3-04(A)(3); and/or

iv. Ensuring that compounded drug preparations maintain quality and sterility until administered, OAC Rule 4729:7-3-04(A)(5); and/or

v. Maintaining drug compounding records pursuant to rule 4729:7-3-06 of the Administrative Code, OAC Rule 4729:7-3-04(A)(6); and/or

b. Immediate-use, sterile compounded drug preparations are exempt from the requirements in rule 4729:7-3-03 of the Administrative Code if all the following criteria are met:

i. The compounding process involves the simple transfer of not more than three commercially manufactured packages of sterile, non-hazardous drugs from the manufacturers' original containers and not more than two entries into any one container or package (e.g., bag, vial) of sterile infusion solution or administration container/device, OAC Rule 4729:7-3-04(B)(1); and/or

ii. The beyond-use date for an immediate-use compounded drug preparation is as follows:

1. Except as provided in paragraph (B)(4)(b) of this rule, no later than six-hours following preparation of the drug, OAC Rule 4729:7-3-04(B)(4)(a); and/or

c. Preparations that do not meet all the requirements listed in paragraph (B) of this rule shall comply with the requirements in rule 4729:7-3-03 of the Administrative Code, OAC Rule 4729:7-3-04(E); and/or

d. Records of drug compounding shall be maintained pursuant to rule 4729:7-3-06 of the Administrative Code, OAC Rule 4729:7-3-04(H).

e. For all compounded drugs prepared pursuant to this rule, a prescriber shall:

i. Inspect and approve the compounding process, OAC Rule 4729:7-3-04(L)(1); and/or

ii. Except as provided in paragraph (M) of this rule, perform medication validation ("final check") prior to the medication being administered, OAC Rule 4729:7-3-04(L)(2); and/or

f. The requirements of paragraph (M)(2) of this rule do not apply to either of the following:

i. A compounded drug preparation is being administered to a patient in the facility by a nurse licensed under Chapter 4723. of the Revised Code pursuant to a prescriber's order and, prior to administration, at least two nurses that are approved by the responsible

person to prepare or administer compounded drugs comply with the requirements in paragraph (N) of this rule, OAC Rule 4729:7-3-04(M)(1); or

ii. A compounded drug preparation is prepared and administered to a patient in the facility by a nurse licensed under Chapter 4723. of the Revised Code pursuant to a prescriber's order and, prior to administration, the same nurse complies with paragraph (N) of this rule, OAC Rule 4729:7-3-04(M)(2); and/or

g. All the following are required to administer a compounded drug preparation in accordance with paragraphs (M)(1) and (M)(2) of this rule:

i. Verify the accuracy of:

1. Drug name, OAC Rule 4729:7-3-04(N)(3)(a); and

2. Drug strength and dosage form, OAC Rule 4729:7-3-04(N)(3)(b); and

3. Drug volume, OAC Rule 4729:7-3-04(N)(3)(c); and

4. Rate of administration, OAC Rule 4729:7-3-04(N)(3)(d); and

5. Route of administration, OAC Rule 4729:7-3-04(N)(3)(e); and

6. Expiration dates/times, OAC Rule 4729:7-3-04(N)(3)(f); and

7. Appearance and physical integrity of the drugs, OAC Rule 4729:7-3-04(N)(3)(g); and/or

ii. Indicate in the compounding record verification was completed, OAC Rule 4729:7-3-04(N)(4); and/or

iii. A licensed prescriber is on-site and immediately available, OAC Rule 4729:7-3-04(N)(5).

10. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following sections of Rule 4729:7-3-06 of the OAC, as effective March 31, 2021, Record Keeping, each violation punishable by a maximum penalty of $1,000:

a. The responsible person shall maintain the following records relating to the compounding of dangerous drugs:

i. All drug orders and records, including logs, relating to the compounding of drugs. Such drug orders and records may be retained by any process providing an exact duplicate of the original order or prescription, OAC Rule 4729:7-3-06(A)(1); and/or

ii. Records of each drug compounded shall, at a minimum, include all the following:

1. The full name of the patient, unless compounded in accordance with paragraph (G)(2) of rule 4729:7-3-04 of the Administrative Code, OAC Rule 4729:7-3-06(A)(3)(a); and/or

2. Name, strength, and dosage form of the compounded drug, OAC Rule 4729:7-3-06(A)(3)(b); and/or

3. Name and quantity of each ingredient, OAC Rule 4729:7-3-06(A)(3)(c); and/or

4. If a controlled substance, the disposition of unused drug(s) and amount, OAC Rule 4729:7-3-06(A)(3)(d); and/or

5. Date and time of preparation, OAC Rule 4729:7-3-06(A)(3)(e); and/or

6. Beyond-use date of the compounded drug, OAC Rule 4729:7-3-06(A)(3)(f); and/or

7. The positive identification of the personnel responsible for compounding the drug, OAC Rule 4729:7-3-06(A)(3)(g); and/or

8. The positive identification of either of the following:

    a. Person or persons performing medication validation prior to the compounded drug being administered, OAC Rule 4729:7-3-06(A)(3)(h)(i); and/or

    b. The prescriber personally furnishing the compounded drug, OAC Rule 4729:7-3-06(A)(3)(h)(ii).

11. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-2-01 of the OAC, Responsible person – terminal distributor, as effective April 25, 2022, each punishable by a maximum penalty of $1,000:

    a. A location licensed as a terminal distributor of dangerous drugs must have a responsible person at all times, OAC Rule 4729:5-2-01(E)(1); and/or

    b. When there is a change of responsible person, the state board of pharmacy shall be notified within ten days of the effective date of the appointment of the new responsible person in a manner determined by the board. For a limited terminal distributor of dangerous drugs license, the notification shall include a drug list required in accordance with agency 4729 of the Administrative Code, OAC Rule 4729:5-2-01(E)(2); and/or

    c. The responsible person to whom the terminal distributor of dangerous drugs license has been issued and all licensed health professionals on duty are responsible for compliance with all state and federal laws, regulations, and rules governing the distribution of dangerous drugs, OAC Rule 4729:5-2-01(E)(4); and/or

d. A responsible person must be physically present at the location for a sufficient amount of time to provide supervision and control of dangerous drugs on-site, OAC Rule 4729:5-2-01(E)(5); and/or

e. The responsible person shall be responsible for ensuring the terminal distributor of dangerous drugs requirements are met, including, but not limited to, the supervision and control of dangerous drugs as required in division (B) of section 4729.55 of the Revised Code, adequate safeguards as required in division (C) of section 4729.55 of the Revised Code, security and control of dangerous drugs and maintaining all drug records otherwise required, OAC Rule 4729:5-2-01(E)(6).

12. Such conduct as set forth in Allegations Section, if proven, constitutes a violation of each of the following divisions of Section 4729.55 of the ORC, as effective October 3, 2023, TDDD license requirements, each violation punishable by a maximum penalty of $1,000:

    a. The applicant is equipped as to land, buildings, and equipment to properly carry on the business of a terminal distributor of dangerous drugs within the category of licensure approved by the board, ORC 4729.55(A); and/or

    b. A… licensed health professional authorized to prescribe drugs… will maintain supervision and control over the possession and custody of dangerous drugs that may be acquired by or on behalf of the applicant, ORC 4729.55(B); and/or

    c. Adequate safeguards are assured to prevent the sale or other distribution of dangerous drugs by any person other than a pharmacist or licensed health professional authorized to prescribe drugs, ORC 4729.55(C).

13. Such conduct as set forth in Allegations Section, if proven, constitutes a violation of each of the following divisions of Section 4729.57(B) of the ORC, as effective April 4, 2023, each violation punishable by a maximum penalty of $1,000:

    a. Violating any rule of the board, ORC Section 4729.57(B)(2); and/or

    b. Violating any provision of this chapter, ORC Section 4729.57(B)(3); and/or

    c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, ORC Section 4729.57(B)(4); and/or

    d. Violating any provision of the federal drug abuse control laws or Chapter 2925. or 3719. of the Revised Code, ORC Section 4729.57(B)(5); and/or

    e. Ceasing to satisfy the qualifications of a terminal distributor of dangerous drugs set forth in section 4729.55 of the Revised Code, ORC Section 4729.57(B)(7); and/or

f. Any other cause for which the board may impose discipline as set forth in rules adopted under section 4729.26 of the Revised Code, ORC Section 4729.57(B)(10).

14. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-4-01 of the OAC, as effective April 25, 2022, each violation punishable by a maximum penalty of $1,000:

    a. Violating any rule of the board, OAC Rule 4729:5-4-01(B)(2); and/or

    b. Violating any provision of Chapter 4729. of the Revised Code, OAC Rule 4729:5-4-01(B)(3); and/or

    c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, OAC Rule 4729:5-4-01(B)(4); and/or

    d. Violating any provision of the federal drug abuse control laws or Chapter 2925. or 3719. of the Revised Code, OAC Rule 4729:5-4-01(B)(5); and/or

    e. Falsely or fraudulently promoting to the public a dangerous drug, except that nothing in this rule prohibits a terminal distributor of dangerous drugs from furnishing information concerning a dangerous drug to a health care provider or another licensed terminal distributor, OAC Rule 4729:5-4-01(B)(6); and/or

    f. Ceasing to satisfy the qualifications of a terminal distributor of dangerous drugs set forth in section 4729.55 of the Revised Code, OAC Rule 4729:5-4-01(B)(7); and/or

    g. Commission of an act that constitutes a misdemeanor that is related to, or committed in, the person's professional practice, OAC Rule 4729:5-4-01(B)(18); and/or

    h. The method used by the terminal distributor to store, possess or distribute dangerous drugs poses serious harm to others, OAC Rule 4729:5-4-01(B)(23).

YOU ARE FURTHER NOTIFIED, in accordance with the provisions of Chapters 119. and 4729. of the Ohio Revised Code, that you are entitled to a hearing before the Ohio Board of Pharmacy, if you request such a hearing within thirty (30) days of the date of the service of this notice.

IF YOU DESIRE A HEARING, such request shall either be mailed to the Ohio Board of Pharmacy, Attn: Legal, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126 or an e-mail request may be sent to legal@pharmacy.ohio.gov (**please note faxes will not be accepted**). **YOUR REQUEST MUST BE RECEIVED ON OR PRIOR TO THE 30TH DAY FOLLOWING THE SERVICE DATE OF THIS NOTICE.** Please note that if you submit a request via email, your request will be acknowledged within one business day of receipt. If you do not receive an acknowledgment, please contact the Board offices at 614-466-4143 and request the legal department. You may appear at such hearing in person, by your attorney, or by such other representative as is permitted to practice before the agency, or you may present your position, arguments or contentions in writing; and, at this hearing, you may also present evidence and

examine any witnesses appearing for and against you. **If you are a business entity, including but not limited to a corporation, limited liability company, or a limited partnership, you must be represented at the hearing by an attorney licensed to practice in the state of Ohio.**

YOU ARE FURTHER ADVISED that if there is no request for such a hearing received by the Board on or prior to the 30th day following the service of this notice, the Ohio Board of Pharmacy, upon consideration of the aforementioned allegations against you, may take action without such a hearing, and may adopt a final order that contains the board's findings. In the final order, the board may impose any of the sanctions listed in division RC 4729.57(A).

If you have questions regarding the Chapter 119. Administrative Hearing process, please e-mail your questions to legal@pharmacy.ohio.gov or call the Board office at 614-466-4143 and ask for the legal department.

BY ORDER OF THE OHIO BOARD OF PHARMACY

Steven W. Schierholt, Esq., Executive Director

SWS/zas/rlj

cc: David Geiger, Ohio Board of Nursing, at: david.geiger@nursing.ohio.gov
Meg LaMantia, Cosmetology and Barber Board, at: meg.lamantia@cos.ohio.gov
Sara Shikhman, Attorney for Respondent, at: Sara.Shikhman@lengealaw.com
Mary Sialongo, Attorney for Respondent, at: mary.sialongo@lengealaw.com